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H19 potentiates let-7 family expression
through reducing PTBP1 binding to their
precursors in cholestasis
Li Zhang1, Zhihong Yang2, Wendong Huang3 and Jianguo Wu 4,5
Abstract
Cholestasis induces the hepatic long non-coding RNA H19, which promotes the progression of cholestatic liver
fibrosis. However, microRNAs that are dysregulated by H19 during cholestasis remain elusive. Using miRNA-
sequencing analysis followed by qPCR validation, we identified marked upregulation of eight members of the let-7
family in cholestatic livers by bile duct ligation (BDL) and H19 overexpression. In particular, the expression of let-7a-1/
7d/7f-1 was highly induced in H19-BDL livers but decreased in H19KO-BDL livers. Interestingly, H19 decreased the
nuclear let-7 precursors as well as the primary transcripts of let-7a-1/7d/7f-1 levels in BDL mouse livers. Bioinformatics,
RNA pull-down, and RNA immunoprecipitation (RIP) assays revealed that the crucial RNA-binding protein
polypyrimidine tract-binding protein 1 (PTBP1), an H19 interaction partner, interacted with the precursors of let-7a-1
and let-7d and suppressed their maturation. Both PTBP1 and let-7 expression was differentially regulated by different
bile acid species in hepatocyte and cholangiocyte cells. Further, H19 negatively regulated PTBP1’s mRNA and protein
levels but did not affect its subcellular distribution in BDL mouse livers. Moreover, we found that H19 restrained but
PTBP1 facilitated the bioavailability of let-7 miRNAs to their targets. Taken together, this study revealed for the first time
that H19 promoted let-7 expression by decreasing PTBP1’s expression level and its binding to the let-7 precursors in
cholestasis.
Introduction
The imprinted oncofetal long non-coding RNA
(lncRNA) H19 is one of the first identified imprinted
lncRNAs and is predominantly distributed in the cyto-
plasm of cells1,2. Due to the methylation modifications
within the differentially methylated region (DMR) of H19
promoters, H19 is only transcribed from the maternally
inherited allele while the paternal H19 allele is not
expressed3. The aberrant H19 expression has been fre-
quently linked to human Beckwith-Wiedemann syndrome
and Silver-Russell syndrome4,5. Intriguingly, H19
maintains a high expression level in embryogenesis but is
barely detectable in most of the tissues after birth except
muscle and heart, implying a crucial role in mammal
development and growth3. Although extensive studies
have revealed important roles of H19 in various cancers6,
the regulation of H19 in human liver diseases is largely
uncovered. Emerging evidence shows that reactivation of
H19 expression exacerbates cholestatic liver fibrosis7 and
the development of fatty liver8. Phenotypically, the high
induction of H19 expression is observed in human cir-
rhotic livers9. Despite these recent advances, the down-
stream molecular networks of H19 in liver pathogenesis
remain elusive.
The polypyrimidine tract-binding protein 1 (PTBP1,
also known as PTB or heteronuclear ribonucleoprotein
(hnRNP) I) is an RNA-binding protein and regulates
precursor mRNA (pre-mRNA) splicing, alternative
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splicing events, and mRNA stability10. PTBP1 has been
implicated in different liver diseases8. PTBP1 complexes
with heterogeneous nuclear RNA in the nucleus to reg-
ulate pre-mRNA processing and other aspects of mRNA
metabolism and transport. PTBP1 has been reported to
associate with multiple lncRNAs. For instance, maternally
expressed 3 (MEG3), another lncRNA, binds to PTBP1 to
control small heterodimer partner mRNA stability and
cholestatic liver injury11, whereas H19 binds PTBP1 and
reprograms hepatic lipid homeostasis8. In most mammals,
there are two tissue-specific isoforms of PTBP. PTBP1 is
widely expressed, while PTBP2 (also called nPTB or
brPTB) is mainly expressed in neurons and testis12. The
PTBP proteins preferentially bind CU tracts (e.g., UCUUC
and CUCUCU, located within a polypyrimidine-rich
context in RNAs). Because all four repeats of quasi-
RNA recognition motif domains in PTBP can bind RNAs,
it is difficult to define one RNA consensus sequence and
to identify RNA targets of PTBP13. The interaction
between PTPB1 with miRNAs has been noticed14, but the
exact role of how PTPB1 regulates miRNA expression
remains to be determined.
Let-7 belongs to a family of miRNAs required for
development timing, tumor suppression, and metabolism
regulation15. To generate a let-7 miRNA, a primary
transcript (pri-let-7) is transcribed by RNA polymerase II
and then subsequently processed. Pri-let-7 is cleaved by
the microprocessor complex, composed of Drosha and its
cofactor DGCR8, to produce precursor let-7 (pre-let-7) in
the nucleus. Pre-let-7 is then exported into the cytoplasm
and cleaved into an ~22-nucleotide duplex by Dicer
complex, followed by unloading into argonaute (AGO)
proteins that are essential components of the RNA-
induced silencing complex (RISC)15,16. In addition to
these basic processing factors, the biogenesis of let-7 is
also tightly regulated by other cellular factors, such as the
RNA-binding proteins (RBPs) LIN28A/B and DIS3L217,18.
Dysregulation of let-7 processing contributes to multiple
pathological processes including cholestatic liver
diseases19.
The goal of this study is to identify aberrant miRNAs
that are regulated by H19 in cholestatic liver fibrosis. In
this study, we determined the role of H19 and its binding
protein PTPB1 in the expression and bioavailability of a
cluster of let-7 miRNAs in cholestasis. The results show
that H19 represses PTPB1 expression in cholestatic
mouse livers, which is permissive to let-7 maturation from
precursors. We also reveal that the bioavailability of let-7
miRNAs is suppressed by H19 but facilitated by PTPB1.
Materials and methods
Mouse models
H19-deficient mice were described previously7. Because
H19 is a paternally imprinted gene, maternal H19-deleted
mice were used for experiments and paternal H19-deleted
mice were used as negative controls. Mice were fed a
standard rodent chow diet (#2918, Teklad global 18%
protein rodent diets; Envigo Bioproducts, Inc) with free
access to water and maintained in a 12 h light/dark cycle
(light on 6 a.m. to 6 p.m.), temperature-controlled (23 °C),
and pathogen-free facility. In vivo experiments were
performed on mice (n= 3–5) at the age of 6 weeks unless
stated otherwise. Considering sex as a biological variable
does not affect the induction of cholestasis after bile duct
ligation (BDL), only male mice were involved in the study
to reduce animal use. For in vivo viral transduction20,
mice (C57BL/6J, Jackson Laboratory, Bar Harbor, ME)
were injected via tail vein with purified adeno-associated
viral vector serotype 8 (AAV8) containing a liver‐specific
thyroxine‐binding globulin promoter driving H19 gene
expression (5 × 1010 virus particles/mouse). The operation
of common BDL has been described previously21. All
experiments were performed in accordance with the
guidelines and regulations approved by the Institutional
Animal Care and Use Committee at the University of
Connecticut.
MicroRNA-sequencing analysis
MicroRNA-sequencing (miR-seq) was conducted at the
Division of Experimental and Translational Genetics,
Children’s Mercy Hospital (Kansas City, MO). A total of
14 livers were subjected to miR-seq analysis (Null-sham,
n= 3; Null-BDL, n= 4; H19-sham, n= 3; and H19-BDL,
n= 4). The read counts of miR-seq were used as criteria
to compare miRNA levels. Quantitative PCR (qPCR)
validation of miRNA expression was conducted in a new
cohort of male mice subjected to sham or BDL (n= 5/
group).
Cell culture
Cell culture procedures for human hepatocellular car-
cinoma (HCC) cell line Huh7 and mouse HCC cell line
Hepa1 have been reported previously and maintained in
Dulbecco’s modified Eagle’s medium with 100 μg/ml
streptomycin, 100 U/ml penicillin, and 10% fetal bovine
serum22,23. Cell culture procedures for mouse small
cholangiocytes (MSCs) and mouse large cholangiocytes
(MLCs) were described previously7. Mouse primary
hepatocytes were isolated and cultured as described
previously24.
Chemicals, plasmids, antibodies, and enzyme-linked
immunosorbent assay kits
Dimethyl sulfoxide (DMSO), cholic acid (CA), cheno-
deoxycholic acid (CDCA), lithocholic acid (LCA), urso-
deoxycholic acid (UDCA), and taurocholic acid (TCA)
were purchased from Sigma-Aldrich (St. Louis, MO) and
the cellular treatment was described previously7. Plasmids
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including pcDNA3-pri-let-7a-1 (#51377), pcDNA3-pri-
let-7d (#51379), and psiCHECK2-let-7 4× (#20930) were
purchased from Addgene. The expression plasmids for
pri-let-7a-1 and pri-let-7d25, and for PTBP111, and the let-
7 luciferase plasmid26 have been described previously.
The following antibodies were used for RNA precipitation
and/or western blotting: PTBP1 (cat. 32-4800; Thermo
Fisher Scientific, Waltham, MA), β-actin (cat. A-1978;
Sigma-Aldrich), Lamin A/C (sc-7292; Santa Cruz Bio-
technology, Santa Cruz, CA), Cyclophilin A (ab58144;
Abcam, Cambridge, UK), AGO2 (cat. 04-642; EMD Mil-
lipore, Burlington, MA), HMGA2 (#8179; Cell Signaling
Technology, Danvers, MA), STAT3 (#9139s; Cell Signal-
ing Technology), TLR4 (sc-293072; Santa Cruz Bio-
technology), and a-Tubulin (sc-5286; Santa Cruz
Biotechnology). Interleukin (IL)-6 enzyme-linked immu-
nosorbent assay (ELISA) kit (Cat. 88-7064-22) was from
Thermo Fisher Scientific. IL-10 ELISA kit (Cat. M1000B)
was from R&D Systems (Minneapolis, MN). The ELISA
assays were performed according to the manufacturers’
instructions.
Reverse transcription-qPCR
RNAs were prepared using Trizol reagent (Thermo
Fisher Scientific)27. For mature (miR) and precursor
miRNAs (pre-miRNA), 1 μg of RNA was reversely tran-
scribed using a miScript II RT Kit (QIAGEN, German-
town, MD). Mature and pre-miRNAs were analyzed by a
miScript Green PCR Kit (QIAGEN) using miScript Pri-
mer Assays for mm-let-7a-5p, mm-let-7d-5p, mm-let-7f-
5p, hsa-let-7a-5p, and hsa-let-7d-5p, and miScript Pre-
cursor Assays for precursors of mm-let-7a-1, mm-let-7d,
and mm-let-7f-1 (QIAGEN). For let-7 target genes and
pri-let-7, total RNAs were reversely transcribed using a
High-Capacity cDNA Reverse Transcription Kit with
RNase Inhibitor (#4374967; Thermo Fisher Scientific) and
qPCR was performed using the SsoAdvanced™ Universal
SYBR® Green Supermix (#1725275; Bio-Rad, Hercules,
CA). The control RNA Snord68 (also known as MBII-
202) was quantitated using TaqMan™ MicroRNA Assay
(ID: 001232) and TaqMan™ Universal PCR Master Mix
(Cat. 4324018) purchased from Thermo Fisher Scientific.
Preparation of RNAs from nuclear and cytoplasmic extracts
As described previously, the nuclear and cytoplasmic
fractions of mouse liver tissues were prepared using a
hypotonic buffer and a high-salt buffer that were supple-
mented with RNase inhibitor (1 U/µl)22. The fractions were
immediately extracted for RNAs using Trizol reagent.
Biotinylated RNA pull-down assay and RNA
immunoprecipitation assay
A biotinylated RNA pull-down assay was performed as
described previously11. Briefly, whole-cell lysates were
incubated fully with purified biotinylated RNA probes that
were synthesized via in vitro transcription. RNA–protein
complexes were further isolated by Streptavidin Sephar-
ose High-Performance beads (GE Healthcare, Marlbor-
ough, MA). The recruited proteins were detected by
western blotting with antibodies. For RNA immunopre-
cipitation (RIP), anti-PTBP1 antibody or mouse immu-
noglobulin G (Sigma) was incubated with ultraviolet-
crosslinked cell lysate for 2 h with gentle shaking. Protein
A/G agarose beads were added to recruit RNA–protein
complexes. RNAs associated with PTBP1 were recovered
with Trizol-chloroform and analyzed by reverse
transcription-qPCR.
Other standard methods
Western blotting, RNA extraction from cells and liver
tissues, qPCR, transient transfection, and luciferase
reporter assays were performed as described pre-
viously22,28–31. The primers were listed in Supplementary
Table 2. Additional results were included in the Supple-
mentary Figure files.
Statistical analysis
All cell-based in vitro experiments were performed in
triplicate and repeated at least two times. All animal-
based in vivo experiments were performed with various
animals (n= 3–5) per group based on an estimated sta-
tistical power for over 80% possibility to find significant
difference. The data were displayed as the mean values ±
standard error of the mean32. Statistical analysis was
carried out using the Student’s t test. P < 0.05 was con-
sidered statistically significant.
Results
Hepatic let-7 family is markedly induced by H19 in BDL-
induced cholestasis
As described previously, a scramble control AAV8 virus
(Null) or an H19-expressing AAV8 virus (H19) were
injected into wild-type (WT) mice via the tail vein to
generate an H19 overexpression mouse model7. We then
performed BDL for 7 days to induce cholestasis in these
mice. As expected, hepatic H19 RNA level was elevated in
H19-BDL vs Null-BDL mice (Fig. S1A). To profile H19-
regulated miRNAs in cholestasis, we performed miR-seq
in Null-BDL and H19-BDL livers, as well as in sham-
operated livers (Null-sham and H19-sham). The hepatic
expression of 32 miRNAs was robustly induced by H19
overexpression either in sham- or BDL-operated mice
(Fig. 1a). Of note, several let-7 family members with
higher basal expression including mmu-let-7f-5p, mmu-
let-7g-5p, mmu-let-7a-5p, and mmu-let-7c-5p, showed up
among these upregulated miRNAs (H19-sham vs Null-
sham; H19-BDL vs Null-BDL) (Fig. 1a, b and Supple-
mentary EXCEL file). In addition, four let-7 family
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members of lower abundance (mmu-let-7i-5p, mmu-let-
7b-5p, mmu-let-7d-5p, and mmu-let-7e-5p) were also
significantly induced in H19-BDL livers, comparing with
Null-BDL mice (Fig. 1b). These results demonstrate that
exogenous H19 overexpression potentiates let-7 family
expression. Although the hepatic endogenous H19
expression is elevated by BDL7,33, unexpectedly, the eight
let-7 miRNAs were plausibly but not significantly induced
by BDL in Null-mice (Null-BDL vs Null-sham); however,
the expression of mmu-let-7f-5p, mmu-let-7g-5p, mmu-
let-7a-5p, and mmu-let-7i-5p was significantly increased
by BDL in H19 mice (H19-BDL vs H19-sham) (Fig. 1b),
suggesting that different from the incompetence of BDL-
induced H19 (7 days), long-term overexpressed H19
(5 weeks) in the liver7 might sensitize cellular context to
predispose cells to BDL induction of let-7. We further
performed qPCR with specific primers to validate the
expression of the above let-7 family members in a new
cohort of Null and H19 mice, which were subjected to
BDL. Let-7a-5p, let-7d-5p, and let-7f-5p displayed
significantly higher expression levels in H19-BDL livers vs
Null-BDL livers (Fig. 1c). Unexpectedly, the expression of
let-7b-5p, let-7c-5p, let-7i-5p, and let-7g-5p was not
induced in H19-BDL vs Null-BDL mice (Fig. S1B), sug-
gesting animal individual variations from two different
cohorts of mice. Of particular note, the expression levels
of let-7a-5p/7d-5p/7f-5p were markedly elevated in pri-
mary hepatocytes isolated from H19-BDL compared to
Null-BDL livers, suggesting that H19 activated let-7
family expression in hepatocytes during cholestasis
(Fig. S1C). We also compared the hepatic expression of
let-7a-5p/7d-5p/7f-5p in H19-sham and Null-sham mice
using qPCR. The results support that H19 potentiates let-
7 expression (Fig. S1D).
We therefore asked whether loss of H19 suppressed let-
7 family expression during cholestasis. As expected, the
hepatic expression of let-7a-5p/7d-5p/7f-5p was sup-
pressed in maternal H19 knockout-BDL mice (HKO-
BDL) vs paternal H19 knockout-BDL mice (Con-BDL)
(Fig. 1d and S1E). Levels of let-7a-5p/7d-5p/7f-5p in the
Fig. 1 H19 increases mature let-7a-5p/7d-5p/7f-5p levels in mouse bile duct ligation (BDL) model. a The heat map showing differential
hepatic expression of let-7 family members. Wild-type (WT) mice were injected with either an empty adeno-associated viral vector serotype 8 (AAV8)
virus (Null) or an H19-expression AAV8 virus (H19) for 1 month to achieve stable gene expression. Then, these mice were subjected to either sham or
BDL surgery for 1 week. Livers were then collected and RNA was extracted and subjected to microRNA-sequencing (miR-seq). The average count
numbers of top 32 miRNAs in each group were plotted. b The count numbers of individual let-7 family members from the miR-seq results were
graphed. c Quantitative PCR (qPCR) of let-7a-5p, let-7d-5p, and let-7f-5p in Null-BDL and H19-BDL mouse livers (n= 5 mice/group). d qPCR of let-7a-
5p, let-7d-5p, and let-7f-5p in BDL-operated paternal H19 knockout (con) and maternal H19 knockout (HKO) mouse livers (n= 5 mice/group). Data
were presented as the mean ± SEM from triplicate assays. *P < 0.05, **P < 0.01, ***P < 0.001; N.S. no significance
Zhang et al. Cell Death and Disease          (2019) 10:168 Page 4 of 13   168 
Official journal of the Cell Death Differentiation Association
primary hepatocytes from HKO-BDL mice were also
much lower than those from the Con-BDL (data not
shown).
Taken together, the above results demonstrated that
H19 positively regulated hepatic let-7 family expression in
cholestatic mice.
Bile acid species exhibit differential potency to regulate
let-7 expression
BDL-induced cholestasis causes the disruption of bile
flow thus the accumulation of bile acids (BAs) in the liver,
which deteriorates biliary epithelia (cholangiocytes) to
promote the development of biliary hyperplasia, intrahe-
patic inflammatory response, and biliary liver fibrosis. In
order to determine whether BAs regulate let-7 family
expression, mouse primary hepatocytes were isolated
fromWT mice and treated with various BAs. Since let-7a-
5p/7d-5p/7f-5p were significantly upregulated by H19 in
cholestatic mouse livers, we focused on the expression of
these three let-7 family members. Overall, the expression
of let-7a-5p, let-7d-5p, and let-7f-5p was induced by dif-
ferent BAs to various extents (Fig. 2a). UDCA showed the
highest potency to induce all three let-7 members,
whereas LCA appeared to moderately repress let-7a-5p
and let-7d-5p expression.
We also examined the effects of BAs on let-7 expression
in MSCs and MLCs. In MSC cells, CA exhibited the
highest potency to induce let-7a-5p, let-7d-5p, and let-7f-
5p expression, whereas CDCA inhibited all three let-7
expression (Fig. 2b). In MLC cells, TCA and LCA induced
let-7a-5p; CA and TCA induced let-7d-5p; CA and LCA
induced let-7f-5p, whereas CDCA inhibited all three let-7
members (Fig. 2c). Because these BAs showed no effects
on H19 promoter luciferase reporter activities in MSC
and MLC cells (Fig. S2A), we postulated that the induc-
tion of let-7a-5p/7d-5p/7f-5p in H19-BDL mice might be
presumably not due to a direct activation of H19 tran-
scription by BAs.
H19 promotes maturation of let-7 miRNAs in BDL-induced
cholestasis
Let-7 family members are expressed either indepen-
dently or as clusters from different genomic location. The
biogenesis of let-7 miRNA is a complex process involving
two key processing steps, i.e. from primary-miRNA (pri-
miR) to the pre-miR and from pre-miR to the miR15. The
murine let-7a-5p/7d-5p/7f-5p are derived from the let-7a-
1/7d/7f-1 cluster in chromosome 13 (Supplementary
Table 1); the pri-miRNAs from this cluster occupy a
substantial portion of all let-7 primary transcripts (~24%
in human)34.
We isolated the nuclear and cytoplasmic fractions of
BDL livers and determined the subcellular levels of the
pri-let-7a-1/7d/7f-1 transcript and let-7 precursors. The
subcellular fractionation efficiency was determined by the
quantification of Rnu6 and Snord68 (Fig. S2B and S2C).
H19 overexpression reduced pri-let-7a-1/7d/7f-1, pre-let-
7a-1 (precursor of let-7a-5p), pre-let-7d (precursor of let-
7d-5p), and pre-7f-1 (precursor of let-7f-5p) in nuclear
fractions of BDL livers; the cytoplasmic levels of the three
precursors were not significantly affected by H19 over-
expression (Figs. 3a, b). Under H19-deficiency condition,
more pri-let-7a-1/7d/7f-1, pre-let-7a-1, pre-let-7d, and
pre-7f-1 accumulated in nuclear fractions of BDL livers; in
addition, cytoplasmic pre-let-7d but not pre-7a-1 and pre-
7f-1 increased after H19 knockout (Figs. 3c, d). Without
subcellular fractionation, we were unable to detect sig-
nificant differences of pri-let-7a-1/7d/7f-1, pre-let-7a-1,
pre-let-7d, and pre-7f-1 between H19-BDL and Null-BDL
livers and unable to discriminate significant changes of
pri-let-7a-1/7d/7f-1 between HKO-BDL and con-BDL
livers; however, the three precursors were significantly
upregulated by H19-deficiency (HKO-BDL vs Con-BDL)
(Fig. S2D and S2E). When normalized to Rnu6 or
Snord68, similar to the un-normalized, we observed the
same alteration trends of these fractionated preforms in
both H19-BDL and HKO-BDL livers, although not sig-
nificant in some cases (Fig. S2F-S2I). These results suggest
that H19 facilitates the processing of mature let-7 miR-
NAs from their preforms. Indeed, when exogenous pri-
let-7a-1 or pri-let-7d were transfected into Huh7 cells,
their mature forms were elevated by H19 overexpression,
confirming that H19 promoted the maturation of let-7
miRNAs (Fig. 3e).
PTBP1 physically interacts with pre-let-7a-1 and pre-let-7d
The biogenesis of let-7 is subjected to the regulations at
genomic, transcriptional, and posttranscriptional levels35.
To date, several RBPs, which recognize let-7 precursors
and affect their processing have been characterized. For
instance, Lin-28 homology B (Lin-28B) serves as a classic
suppressor of let-7 biogenesis via binding to their pre-
cursors17. PTPB1 has been identified as an interacting
partner of H198 and is involved in RNA processing,
transport, and metabolism through a direct association
with target RNAs12,36.
To determine whether PTBP1 participates in the bio-
genesis of let-7 miRNAs, online bioinformatics tools
(RBPmap and starBase v2.0) were employed to predict
PTBP1-binding motifs in the stem-loop sequences of both
mouse and human let-7a-1, let-7f-1, and let-7d (they are
clustered in the same chromosome). RBPmap analysis
revealed that there were multiple potential PTBP1-
binding motifs within pre-let-7a-1 and pre-let-7d but
not within pre-let-7f-1 in both humans and mice (Fig. 4a
and Fig. S3).
Biotinylated RNA pull-down assays with RNA probes of
pre-let-7a-1 and pre-let-7d were performed to examine
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the interactions between PTBP1 and pre-let-7a-1/pre-let-
7d in human Huh7 and mouse Hepa1 cell lines. The
results showed that PTBP1 physically interacted with pre-
let-7a-1 and pre-let-7d in both cell lines (Fig. 4b). Pre-let-
7a-1 probes recruited more PTPB1 in H19 overexpression
(+) Huh7 cells than control (−) cells, suggesting that H19
Fig. 2 The expression of let-7a-5p/7d-5p/7f-5p is regulated by bile acids in hepatic cells. a–c Quantitative PCR of let-7a-5p, let-7d-5p, and let-
7f-5p in mouse primary hepatocytes (a), small cholangiocytes (MSCs) (b), and large cholangiocytes (MLCs) (c). Cells were treated with cholic acid (CA,
100 µM), taurocholic acid (TCA, 100 µM), chenodeoxycholic acid (CDCA, 100 µM), ursodeoxycholic acid (UDCA, 100 µM), or lithocholic acid (LCA,
10 µM) for 24 h. Data were shown as mean ± SEM from triplicate assays. *P < 0.05, **P < 0.01 vs dimethyl sulfoxide
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facilitated the association of PTBP1 with pre-let-7a-1
(Fig. 4b). Of note, the different sizes of PTBP1 detected in
the pull-down assays were due to post-translational
phosphorylation and/or acetylation modifications37.
Reciprocally, immunoprecipitation (RIP) assays using
PTPB1 antibody further revealed the interactions
between PTBP1 and pre-let-7a-1/pre-let-7d in Huh7 cells
(Fig. 4c).
H19 negatively regulates PTBP1 expression in mouse
cholestatic livers
Next, we examined whether H19 affected PTBP1
expression in BDL-induced cholestasis. qPCR results
demonstrated that PTPB1 mRNA was significantly
decreased in H19-BDL livers vs Null-BDL livers, and
increased in HKO-BDL livers vs Con-BDL livers (Fig. 5a).
Similarly, PTBP1 protein levels were downregulated by
H19 overexpression and upregulated by H19 depletion
(Fig. 5b). Corresponding to the induction of H19 in
cholestasis, we examined PTBP1 mRNA expression in
BA-insulted cells in vitro and found that it was sig-
nificantly decreased by the treatments with several BAs in
MSC cells (Fig. S4). In addition, CDCA reduced PTBP1
mRNA in hepatocytes, whereas UDCA decreased PTBP1
mRNA in MLC cells.
The subcellular shuttling between the cytoplasm and
nucleus is critical to PTBP1’s function38. In H19-BDL
livers, PTBP1 protein was reduced in both cytoplasmic
and nuclear fractions in comparison with Null-BDL livers
(Fig. 5c). The simultaneous increase of PTBP1 protein in
both subcellular fractions was found in H19-deficient
cholestatic (HKO-BDL) livers (Fig. 5d). Interestingly, the
indispensable miRNA processing factor protein AGO2
(also named as RISC catalytic component) decreased in
cytoplasmic fractions but accumulated in nuclear frac-
tions of H19-BDL livers (Fig. 5c); in addition, AGO2 was
remarkably increased in the cytoplasmic fractions of
HKO-BDL livers (Fig. 5d). These suggest that H19 might
dampen the function of RISC through inhibiting AGO2 to
regulate miRNA bioavailability. Overall, these findings
indicated that H19 suppressed PTBP1 expression without
altering its subcellular localization in cholestatic mouse
livers.
H19/PTBP1 modulates the expression and bioavailability
of let-7a-5p/7d-5p in vitro
To further understand the regulation of let-7 miRNAs
by H19/PTBP1, we selected let-7a-5p/7d-5p as two
representative miRNAs to further examine the effects of
H19/PTBP1 on the expression of let-7 miRNAs in vitro.
Fig. 3 H19 regulates the levels of let-7 primary transcripts and precursors in cholestatic mouse livers. a, b Quantitative PCR (qPCR) of the
expression of pri-let-7a-1/7d/7f-1 (a) and pre-let-7a-1/7d/7f-1 (b) in the cytoplasmic and nuclear extracts of Null-BDL and H19-BDL mouse livers (n= 5
mice/group). c, d qPCR of the expression of pri-let-7a-1/7d/7f-1 (c) and pre-let-7a-1/7d/7f-1 (d) in the cytoplasmic and nuclear extracts of control
(con) and maternal H19 knockout (HKO) mouse BDL livers (n= 5 mice/group). e qPCR of the expression of let-7a-5p and let-7d-5p in Huh7 cells
transfected with the indicated plasmids for 48 h. Data were shown as mean ± SEM from triplicate assays. N.S. no significance; *P < 0.05, **P < 0.01
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H19 overexpression in Huh7 cells dramatically increased
the levels of let-7a-5p and let-7d-5p, while PTBP1 over-
expression had a suppressive effect on their levels
(Fig. 6a).
Functionally, we used let-7 biosensor psiCHECK2-let-7
4×, which contains four let-7-binding sites downstream of
the renilla luciferase (Rluc) coding region, to determine
how H19/PTBP1 regulates let-7 miRNAs’ bioavailability.
Two HCC cell lines Huh7 and Hepa1, both of which
contained detectable levels of let-7a-5p/7d-5p, were
transfected with psiCHECK2-let-7 4× together with
empty pcDNA3, PTBP1, or H19 plasmid. The inhibition
of let-7a-5p/7d-5p on Rluc activity was confirmed via co-
transfection of psiCHEK2-let-7 4× and let-7a-5p/7d-5p
(Fig. S5). The Rluc activity was decreased after PTBP1
overexpression, indicating that PTBP1 facilitated let-7a-
5p and let-7d-5p to target their binding sites within Rluc
mRNA and inhibited Rluc expression. In contrast, H19
overexpression prevented let-7a-5p/7d-5p from binding
to Rluc mRNA and increased Rluc activity as compared
with the negative control (pcDNA3) (Fig. 6b). These
results are consistent with the previous finding that
H19 serves as a “Sponge” of let-7 to restrain its
bioavailability26.
Therefore, these findings suggested that H19 increased
let-7a-5p/7d-5p production, with an inhibitory effect on
the bioavailability to their targets, and that PTBP1
decreased let-7a-5p/7d-5p production and promoted their
bioavailability. We examined the expression levels of
several let-7 targets to interrogate the functional sig-
nificance of H19 regulation of let-7 in BDL-induced
cholestatic livers, considering the opposite effects of H19
on let-7 expression and bioavailability. The hepatic
mRNA expression of several inflammation-related target
genes of let-7, including Stat339, Hmga240,41, Tlr442, Il643,
and Il1043 significantly increased in H19-BDL vs Null-
Fig. 4 Polypyrimidine tract-binding protein 1 (PTBP1) physically interacts with pre-let-7a-1/7d. a Predicated PTBP1-binding sites in the human
pre-let-7a-1/7d using RBPmap (http://rbpmap.technion.ac.il). The position, genomic motifs, occurrence, z-score, and P-value were shown. b RNA pull-
down followed by western blotting. Either cell lysates of Hepa1 or Huh7 or cell lysates prepared from Hepa1 or Huh7 cells transfected without (−) or
with (+) H19 overexpression plasmid were incubated with biotin-labeled pre-let-7d (sense or antisense) or pre-let-7a-1 (sense or antisense) probes.
After pull down, the recruited PTBP1 to probes was examined by western blotting with anti-PTBP1 antibody. c RNA-immunoprecipitation (RIP) assay
to detect the interactions between PTBP1 and pre-let-7a-1 or pre-let-7d using anti-PTBP1 or immunoglobulin GIgG (negative control) in Huh7 cells.
Data were shown as mean ± SEM from triplicate assays. ***P < 0.001
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BDL livers (Fig. 6c), suggesting H19 might decrease let-7
bioavailability to exacerbate BDL-induced hepatic
inflammatory response, which is in concordance with the
previous finding that H19-BDL livers develop more severe
liver injury and fibrosis than Null-BDL livers7. In contrast,
the hepatic mRNA expression of metabolism-related let-7
target genes Lpl44, Igf1r45, and Insr45 did not show sig-
nificant change after H19 overexpression (Fig. 6d). H19-
BDL livers displayed more protein expression of STAT3
and TLR4, with an undetectable level of HMGA2 revealed
by western blotting (Fig. 6e). Further, ELISA revealed that
IL-6 but not IL-10 increased in H19-BDL vs Null-BDL
livers (Fig. 6f).
Discussion
The dysregulation of let-7 miRNAs is found in chole-
static liver disorders19,46. In this study, we reveal that
lncRNA H19 promotes the biogenesis and expression of a
cluster of let-7 miRNAs, including let-7a-5p, let-7d-5p,
and let-7f-5p, in cholestatic mouse livers, and functionally
suppresses their bioavailability. We also find that H19
antagonizes the expression of PTBP1, an H19-interacting
protein, which associates with pre-let-7d and pre-let-7a-1
and inhibits let-7 biogenesis but promotes their bioavail-
ability (Fig. 7).
Because of the hydrophobic or hydrophilic nature as
well as the different affinity to BA receptors, BAs act as
signaling molecules but display differential potency to
regulate gene expression47. We find that the hydrophilic
UDCA significantly and to the maximal extent increases
the expression of let-7a-5p/7d-5p/7f-5p in primary
hepatocytes but almost has no effect in MLC and MSC
cells (Fig. 2). A previous study shows that H19 is only
induced by LCA among several BAs in primary hepato-
cytes7. The inconsistent induction of H19 and let-7
miRNAs by UDCA in primary hepatocytes suggest that
UDCA may upregulate let-7a-5p/7d-5p/7f-5p in hepato-
cytes independent of H19. Indeed, H19 is mainly
expressed in cholangiocytes and cholangiocyte-derived
exosomes, which are the sources of H19 in hepatocytes
during cholestatic disease progression48. We show that
LCA moderately decreases let-7a-5p and let-7d-5p in
primary hepatocytes, which apparently disputes a positive
correlation between H19 and let-7 miRNAs expression.
Thus, isolating primary hepatocytes from cholestatic
livers may help to establish a positive expression corre-
lation between let-7 and H19 in hepatocytes. Indeed, in
primary hepatocytes isolated from cholestatic mouse
livers, the expression of let-7a-5p/7d-5p/7f-5p was
enhanced by H19 overexpression (Fig. S1C). Furthermore,
CA, TCA, or both induces the expression of let-7a-5p/7d-
5p/7f-5p in MSC and MLC cells (Fig. 2b, c), which sup-
ports a positive correlation between H19 and let-7
miRNA expression.
We show that the hydrophobic BA CDCA, the most
efficacious endogenous FXR ligand, which is in low level
or absent in cholangiocytes49, decreases the expression of
let-7a-5p/7d-5p/7f-5p in MSC and MLC cells, suggesting
Fig. 5 H19 decreases polypyrimidine tract-binding protein 1 (PTBP1) expression in cholestasis. (a) Quantitative PCR of PTBP1 expression in
control and H19-overexpression or maternal H19 knockout bile duct ligation (BDL) mouse livers. Left, Null-BDL vs H19-BDL; right, Con-BDL vs HKO-
BDL. Data were shown as mean ± SEM from triplicate assays (n= 5 mice/group). ***P < 0.001. b Western blotting of PTBP1 in mouse livers as a. c, d
Western blotting of the expression of indicated proteins in cytoplasm and nucleus fractions prepared from BDL mouse livers. Cyclophilin A was used
as a cytoplasmic fraction maker and Lamin A/C was used as a nuclear fraction marker. c, d Protein samples were pooled from five individual mice per
group
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that let-7 expression can be induced independent of FXR.
In vitro cultured MSC and MLC cells might not well
reflect the precise regulation of let-7 expression by H19
in vivo. Therefore, isolating primary cholangiocytes from
cholestatic livers to examine let-7 and H19 levels will be
the future directions. Further, the dysregulated levels of
let-7a-5p/7d-5p/7f-5p in H19-modulated cholestatic
mouse livers is a consequence of multiple additive/
synergistic effects of H19 not only on BA components but
also on other biological processes, such as intrahepatic
inflammation and biliary proliferation.
It has been shown that PTBP1 is in complex with AGO2
and miRNAs and is involved in let-7-loaded miRNA-
induced silencing complex in human cells, indicating
potential roles of PTBP1 in miRNA-mediated gene reg-
ulation50. In this study, for the first time, we identify
PTBP1 as a novel pre-let-7d/pre-let-7a-1 interacting
partner, which expands the regulatory network of let-7
biogenesis. The binding of PTBP1 to pre-let-7 might
reduce their accessibility to Dicer and/or degrade pre-let-
7 directly by recruiting certain RNases or miRNAs, which
have been used as mechanisms by other RBPs, such as
LIN28A/B and hnRNP A1, to post-transcriptionally reg-
ulate let-7 biogenesis17,25,51. The exact mechanisms by
which PTPB1 suppresses let-7 biogenesis need further
investigation.
Under pathological conditions, the association between
RBPs and RNAs can be dynamically enhanced or
Fig. 6 H19/PTBP1 modulates the expression and bioavailability of let-7a-5p/7d-5p in vitro. a Quantitative PCR (qPCR) of let-7a-5p and let-7d-
5p in Huh7 cells transfected with pcDNA3, H19, or polypyrimidine tract-binding protein 1 (PTBP1) plasmids for 48 h. b Luciferase reporter assays using
psiCHECK2-let-7 4× (top) in Huh7 (left) and Hepa1 (right) cells transfected with pcDNA3, PTBP1, and H19 plasmids. NC none transfected. The renillar
luciferase (RLuc) activity was determined 24 h after transfection. c, d qPCR of let-7 target genes in Null-BDL and H19-BDL mouse livers as Fig. 1c. e
Western blotting of indicated proteins in Null-BDL and H19-BDL mouse livers (left). Protein samples were from three individual mice per group. The
band densitometry was quantified using ImageJ and relative protein expression was graphed (right). f Enzyme-linked immunosorbent assay of
interleukin (IL)-6 and IL-10 in Null-BDL and H19-BDL mouse livers (n= 5 mice/group). N.S. no significance; *P < 0.05, **P < 0.01
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disturbed. We find that H19 significantly induces let-7a-
5p/7d-5p/7f-5p in cholestatic mouse livers and facilitates
the interactions between PTBP1 and pre-let-7d/pre-let-
7–7a-1 in vitro, suggesting that the PTBP1/let-7 miRNAs
may be involved in the progression of cholestasis. A
handful of studies show that let-7 family members are
engaged in several biliary diseases. For example, let-7i is
able to modulate lipopolysaccharide receptor Toll-like
receptor (TLR) expression in inflammation processes in
cholangiocytes52. Inhibition of let-7a in BDL mice
increases intrahepatic bile duct mass and the expression
of nerve growth factor53. Let-7d is downregulated in pri-
mary biliary cirrhosis (PBC) liver tissues compared with
normal tissues in human54. Let-7b is significantly
decreased in the peripheral blood cells of PBC patients55.
Therefore, we will continue to determine the association
between PTBP1 and pre-let-7d/pre-let-7a-1 in the BDL
mouse model and reveal their expression correlation in
human cholestatic liver diseases, which will shed light on
the molecular mechanisms of pathogenesis and progres-
sion of human cholestatic liver diseases.
There are still some open questions: (1) are H19,
PTBP1, and pre-let-7 integrated into the same complex?
(2) If so, what are other functional factors including
proteins and RNAs? (3) Although H19 associates with
PTBP1 and reduces its mRNA and protein expression, it
is unknown whether H19 regulates PTBP1 tran-
scriptionally or post-transcriptionally. (4) The interaction
between H19 and pre-let-7 needs to be elucidated. (5) The
intriguing part of this study is that H19 potentiates let-7
expression but decreases its bioavailability. The “Sponge”
function of H19 to restrain let-7 bioavailability has been
revealed15,26,44. We find that H19 decreases the cyto-
plasmic level of AGO2, an essential component of the
RISC to silence gene expression; this may also partially
explain the upregulation of let-7 target genes in H19-BDL
livers (Fig. 6). The biological significance of let-7 miRNA
upregulation in cholestatic livers needs further investiga-
tion. It is unknown whether their upregulation by H19 is a
feedback to dampen H19’ pathological effects through
inhibiting let-7 target genes, which are upregulated by
H19.
A pri-let-7a-1/7d/7f-1 transcript from the locus on
mouse chromosome 13 can produce a high percentage of
let-7a-5p, let-7d-5p, and let-7f-5p. However, let-7a-5p can
also originate from chromosome 9 and let-7f-5p can be
derived from chromosome X. We show that PTBP1
interacts with pre-let-7a-1 and pre-let-7d, and decreases
let-7a-5p and let-7d-5p (Figs. 4 and 6). However, pre-let-
7f-1 potentially does not have any PTBP1 binding motif. It
still needs to determine whether PTBP1 affects the let-7f-
5p level.
H19 functions via physically associating with its part-
ners. Nuclear H19 controls a series of Imprinted Gene
Network genes to modulate embryo growth through
functional interaction with methyl-CpG-binding domain
protein 1 to establish H3K9me3 repressive markers at
their DMRs1. Cytoplasmic H19 can bind to a RBP, human
antigen R, and prohibit miR-675 processing to limit the
growth of placenta before birth56. The implication of
H19/PTBP1 in regulating let-7 expression and bioavail-
ability may help to delineate the molecular mechanisms of
let-7 dysregulation in various human diseases.
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Fig. 7 Schematic of H19/PTBP1 regulation of let-7a-5p/7d-5p
expression in cholestasis. Under a normal condition, polypyrimidine
tract-binding protein 1 (PTBP1) interacts with H19 and is also
incorporated into the precursors of let-7a-1 and let-7d. The binding of
PTPB1 to precursors of let-7 might prevent the biogenesis of mature
let-7 miRNAs. During cholestasis, H19 expression is activated, which
leads to the reduction of PTPB1. Concomitantly, the suppressive effect
of PTPB1 on the processing of pre-let-7a-1 and pre-let-7d is alleviated.
Therefore, the production of let-7a-5p and let-7d-5p is potentiated
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